<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00825812</url>
  </required_header>
  <id_info>
    <org_study_id>P05768</org_study_id>
    <secondary_id>19.4.324</secondary_id>
    <nct_id>NCT00825812</nct_id>
  </id_info>
  <brief_title>Comparison of 2.0 mg/kg Sugammadex and Neostigmine at Reappearance of T2 in Chinese and European Subjects (Study 19.4.324)(P05768AM1)(COMPLETED)</brief_title>
  <official_title>A Multi-center, Randomized, Parallel-group, Active-controlled, Safety-assessor Blinded Trial, Comparing the Efficacy and Safety of 2.0 mg.Kg-1 Sugammadex With 50 μg.Kg-1 Neostigmine Administered at Reappearance of T2 After Rocuronium in Chinese and European ASA I-III Subjects Undergoing Elective Surgery Under Propofol Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present trial was set up to evaluate the efficacy and safety of 2.0 mg.kg-1 sugammadex
      compared to neostigmine administered at reappearance of T2 in Chinese and Caucasian subjects
      for registration purposes in China.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time From Start of Administration of Investigational Medicinal Product (IMP) to Recovery of the T4/T1 Ratio to 0.9.</measure>
    <time_frame>start of administration of sugammadex/neostigmine to recovery from neuromuscular blockade</time_frame>
    <description>Neuromuscular functioning was monitored by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation was to continue until the ratio of the magnitude of the fourth twitch (T4) to first twitch (T1) reached &gt;= 0.9. The greater the T4/T1 ratio the greater the recovery from neuromuscular blockade, with a value of 1.0 representing full recovery.
The primary analysis was the comparison between sugammadex &amp; neostigmine among Chinese subjects; other comparisons were secondary.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time From Start of Administration of IMP to Recovery of the T4/T1 Ratio to 0.7 and 0.8.</measure>
    <time_frame>start of administration of sugammadex/neostigmine to recovery from neuromuscular blockade</time_frame>
    <description>Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. The greater the T4/T1 ratio the greater the recovery from neuromuscular blockade.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">308</enrollment>
  <condition>Anesthesia, General</condition>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>Sugammadex in Caucasian Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neostigmine in Caucasian Subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex in Chinese Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neostigmine in Chinese Subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 2.0 mg/kg sugammadex was administered.</description>
    <arm_group_label>Sugammadex in Caucasian Subjects</arm_group_label>
    <arm_group_label>Sugammadex in Chinese Subjects</arm_group_label>
    <other_name>Org 25969, Bridion®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neostigmine</intervention_name>
    <description>After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 50 µg/kg neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.</description>
    <arm_group_label>Neostigmine in Caucasian Subjects</arm_group_label>
    <arm_group_label>Neostigmine in Chinese Subjects</arm_group_label>
    <other_name>Neostigmine with atropine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Subjects who are willing to provide informed consent; be between 18 and 64 years old; are
        American Society of Anaesthesiology (ASA) class 1-3 (extremes included); scheduled for
        elective surgery under general anesthesia, allowing stable neuromuscular monitoring, which
        requires neuromuscular blockade using rocuronium; be compliant with the dose/visit
        schedules, and use an accepted method of contraception (if applicable).

        For China only: Subjects of Chinese descent born in China, never emigrated out of China and
        have a Chinese home address. For Europe only: Subjects of Caucasian descent born in Europe,
        never emigrated out of Europe and have a European home address.

        Exclusion Criteria:

        -Subjects with expected difficult intubation, neuromuscular disorders affecting
        neuromuscular blockade, significant renal/hepatic dysfunction, use of a tourniquet,
        (family) history of malignant hyperthermia, allergy to general anesthesia medications,
        contraindication to study drugs, breast feeding, pregnant, participation in previous or new
        trials, a clinically significant condition that may interfere with the trial, or membership
        in the (family of) study/sponsor staff.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Belgium</country>
    <country>China</country>
    <country>Denmark</country>
    <country>Norway</country>
  </removed_countries>
  <results_reference>
    <citation>Wu X, Oerding H, Liu J, Vanacker B, Yao S, Dahl V, Xiong L, Claudius C, Yue Y, Huang Y, Abels E, Rietbergen H, Woo T. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiol. 2014 Jul 12;14:53. doi: 10.1186/1471-2253-14-53. eCollection 2014.</citation>
    <PMID>25187755</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2009</study_first_submitted>
  <study_first_submitted_qc>January 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2009</study_first_posted>
  <results_first_submitted>July 22, 2011</results_first_submitted>
  <results_first_submitted_qc>July 22, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 18, 2011</results_first_posted>
  <last_update_submitted>October 30, 2015</last_update_submitted>
  <last_update_submitted_qc>October 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>Atropine</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>308 participants were randomized</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sugammadex in Caucasian Subjects</title>
          <description>At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.</description>
        </group>
        <group group_id="P2">
          <title>Neostigmine in Caucasian Subjects</title>
          <description>At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.</description>
        </group>
        <group group_id="P3">
          <title>Sugammadex in Chinese Subjects</title>
          <description>At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.</description>
        </group>
        <group group_id="P4">
          <title>Neostigmine in Chinese Subjects</title>
          <description>At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="126"/>
                <participants group_id="P4" count="121"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>TREATED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="120"/>
                <participants group_id="P4" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="120"/>
                <participants group_id="P4" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Never entered follow up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sugammadex in Caucasian Subjects</title>
          <description>At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.</description>
        </group>
        <group group_id="B2">
          <title>Neostigmine in Caucasian Subjects</title>
          <description>At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.</description>
        </group>
        <group group_id="B3">
          <title>Sugammadex in Chinese Subjects</title>
          <description>At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.</description>
        </group>
        <group group_id="B4">
          <title>Neostigmine in Chinese Subjects</title>
          <description>At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="120"/>
            <count group_id="B4" value="111"/>
            <count group_id="B5" value="291"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.0" spread="10.3" lower_limit="27" upper_limit="64"/>
                    <measurement group_id="B2" value="51.9" spread="7.3" lower_limit="34" upper_limit="63"/>
                    <measurement group_id="B3" value="39.9" spread="10.8" lower_limit="19" upper_limit="63"/>
                    <measurement group_id="B4" value="39.4" spread="10.8" lower_limit="18" upper_limit="61"/>
                    <measurement group_id="B5" value="42.2" lower_limit="18" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="86"/>
                    <measurement group_id="B5" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time From Start of Administration of Investigational Medicinal Product (IMP) to Recovery of the T4/T1 Ratio to 0.9.</title>
        <description>Neuromuscular functioning was monitored by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation was to continue until the ratio of the magnitude of the fourth twitch (T4) to first twitch (T1) reached &gt;= 0.9. The greater the T4/T1 ratio the greater the recovery from neuromuscular blockade, with a value of 1.0 representing full recovery.
The primary analysis was the comparison between sugammadex &amp; neostigmine among Chinese subjects; other comparisons were secondary.</description>
        <time_frame>start of administration of sugammadex/neostigmine to recovery from neuromuscular blockade</time_frame>
        <population>The Full Analysis Set (FAS) population included all subjects who received randomized treatment and had at least one efficacy measurement. In the event of missing data, imputed data were used for analysis.
291 subjects received IMP, of whom two had no efficacy measurements at all. Hence the FAS consisted of 289 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Sugammadex in Caucasian Subjects</title>
            <description>At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.</description>
          </group>
          <group group_id="O2">
            <title>Neostigmine in Caucasian Subjects</title>
            <description>At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.</description>
          </group>
          <group group_id="O3">
            <title>Sugammadex in Chinese Subjects</title>
            <description>At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.</description>
          </group>
          <group group_id="O4">
            <title>Neostigmine in Chinese Subjects</title>
            <description>At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Start of Administration of Investigational Medicinal Product (IMP) to Recovery of the T4/T1 Ratio to 0.9.</title>
          <description>Neuromuscular functioning was monitored by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation was to continue until the ratio of the magnitude of the fourth twitch (T4) to first twitch (T1) reached &gt;= 0.9. The greater the T4/T1 ratio the greater the recovery from neuromuscular blockade, with a value of 1.0 representing full recovery.
The primary analysis was the comparison between sugammadex &amp; neostigmine among Chinese subjects; other comparisons were secondary.</description>
          <population>The Full Analysis Set (FAS) population included all subjects who received randomized treatment and had at least one efficacy measurement. In the event of missing data, imputed data were used for analysis.
291 subjects received IMP, of whom two had no efficacy measurements at all. Hence the FAS consisted of 289 subjects.</population>
          <units>minutes</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="119"/>
                <count group_id="O4" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1.3" upper_limit="1.5"/>
                    <measurement group_id="O2" value="6.7" lower_limit="5.5" upper_limit="8.0"/>
                    <measurement group_id="O3" value="1.6" lower_limit="1.5" upper_limit="1.7"/>
                    <measurement group_id="O4" value="9.1" lower_limit="8.0" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The primary analysis was the comparison of the two treatments among Chinese subjects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean time to recovery</param_type>
            <param_value>5.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.9</ci_lower_limit>
            <ci_upper_limit>6.6</ci_upper_limit>
            <estimate_desc>Ratio of time to recovery of 0.9 T4/T1 ratio (neostigmine time / sugammadex time).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A key secondary analysis was the comparison of the two treatments among Caucasian subjects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean time to recovery</param_type>
            <param_value>4.8</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_lower_limit>3.7</ci_lower_limit>
            <ci_upper_limit>6.0</ci_upper_limit>
            <estimate_desc>Ratio of time to recovery of 0.9 T4/T1 ratio (neostigmine time / sugammadex time).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A key secondary analysis was the comparison for equivalence between Chinese subjects and Caucasian subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence was considered if the 97.5% confidence interval (CI) for median difference in recovery time (T4/T1 ratio to 0.9) was within the pre-specified range of -60 to +60 seconds.</non_inferiority_desc>
            <param_type>median difference (seconds)</param_type>
            <param_value>7</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_lower_limit>-5</ci_lower_limit>
            <ci_upper_limit>21</ci_upper_limit>
            <estimate_desc>Estimated median difference (Chinese - Caucasian) in seconds for the time to recovery of the T4/T1 ratio to 0.9 (after sugammadex).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Start of Administration of IMP to Recovery of the T4/T1 Ratio to 0.7 and 0.8.</title>
        <description>Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. The greater the T4/T1 ratio the greater the recovery from neuromuscular blockade.</description>
        <time_frame>start of administration of sugammadex/neostigmine to recovery from neuromuscular blockade</time_frame>
        <population>The Full Analysis Set population included all subjects who received randomized treatment and had at least one efficacy measurement. In the event of missing data, imputed data were used for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Sugammadex in Caucasian Subjects</title>
            <description>At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.</description>
          </group>
          <group group_id="O2">
            <title>Neostigmine in Caucasian Subjects</title>
            <description>At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.</description>
          </group>
          <group group_id="O3">
            <title>Sugammadex in Chinese Subjects</title>
            <description>At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.</description>
          </group>
          <group group_id="O4">
            <title>Neostigmine in Chinese Subjects</title>
            <description>At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Start of Administration of IMP to Recovery of the T4/T1 Ratio to 0.7 and 0.8.</title>
          <description>Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. The greater the T4/T1 ratio the greater the recovery from neuromuscular blockade.</description>
          <population>The Full Analysis Set population included all subjects who received randomized treatment and had at least one efficacy measurement. In the event of missing data, imputed data were used for analysis.</population>
          <units>minutes</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="119"/>
                <count group_id="O4" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Recovery of T4/T1 ratio to 0.7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.9" upper_limit="1.1"/>
                    <measurement group_id="O2" value="3.4" lower_limit="3.0" upper_limit="3.8"/>
                    <measurement group_id="O3" value="1.1" lower_limit="1.1" upper_limit="1.2"/>
                    <measurement group_id="O4" value="4.4" lower_limit="4.0" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recovery of T4/T1 ratio to 0.8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="1.1" upper_limit="1.3"/>
                    <measurement group_id="O2" value="4.6" lower_limit="4.0" upper_limit="5.4"/>
                    <measurement group_id="O3" value="1.3" lower_limit="1.2" upper_limit="1.4"/>
                    <measurement group_id="O4" value="6.0" lower_limit="5.4" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sugammadex in Caucasian Subjects</title>
          <description>At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.</description>
        </group>
        <group group_id="E2">
          <title>Neostigmine in Caucasian Subjects</title>
          <description>At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.</description>
        </group>
        <group group_id="E3">
          <title>Sugammadex in Chinese Subjects</title>
          <description>At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.</description>
        </group>
        <group group_id="E4">
          <title>Neostigmine in Chinese Subjects</title>
          <description>At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anastomotic leak</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Incision site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="84" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="31"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="120"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="120"/>
                <counts group_id="E4" events="16" subjects_affected="16" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Sensation of foreign body</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anaesthetic complication cardiac</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="28" subjects_affected="28" subjects_at_risk="120"/>
                <counts group_id="E4" events="26" subjects_affected="26" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E2" events="20" subjects_affected="14" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="29"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="31"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Procedural vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="120"/>
                <counts group_id="E4" events="23" subjects_affected="22" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Increased upper airway secretion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hypotensive anaesthesia procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI must not publish/publicly present any interim results without prior written consent of sponsor. The PI must provide copies of material for sponsor to review, 45 days prior to submission for publication/presentation. The sponsor may review/comment. If the parties disagree on the appropriateness of the data analysis and presentation, the PI must agree to meet prior to submission for publication/presentation to make good faith efforts to discuss and resolve any issues or disagreement.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

